Deciphering Neuromyelitis Optica Spectrum Disorder: Addressing Real Clinician Questions Concerning Diagnosis and Management
Deciphering Neuromyelitis Optica Spectrum Disorder: Addressing Real Clinician Questions Concerning Diagnosis and Management is organized by Medical Education Resources (MER), Efficient LLC.
Course opens: 06/20/2023
Course expires: 06/20/2024
Description:
Though neuromyelitis optica spectrum disorder (NMOSD) has had a specific lab marker (AQP4 antibody) for many years, its relapsing nature and overlapping syndromes still cause it to be confused with multiple conditions such as multiple sclerosis (MS), leading to inappropriate and even harmful treatment. The emergence of similarly presenting MOG antibody disease (MOGAD) as its own entity has further complicated the picture. Thankfully, FDA-approved targeted therapies (eculizumab, inebilizumab, satralizumab) have recently become available to treat NMOSD. But such rapid advancement alongside continually evolving understanding of serotypes, biomarkers, and neuroimaging signs has created an environment prone to knowledge and performance deficiencies.
To mitigate these gaps and ensure clinicians have the information and tools to appropriately integrate recent advances into practice, this unique 1.5-hour symposium, originally presented at the Consortium of MS Centers (CMSC) annual meeting, is structured around actual questions submitted by neurologists who treat but do not specialize in NMOSD to capture the most prevalent real challenges faced in the clinic today. The faculty then utilize their own experiences and supporting literature to address these questions and expand upon contemporary strategies.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
• Identify key clinical and radiological features that distinguish NMOSD alongside rising tools for prognosis in order to more rapidly diagnose and tailor clinical strategies to individuals with both AQP4-IgG seropositive and seronegative presentations of the disease
• Assess clinical investigator perspectives on the optimal management of acute attacks, including appropriate corticosteroid and plasma exchange protocols, and subsequent follow-up in order to maximize acute recovery and formulate effective management plans long term
• Describe the roles of, most recent data evaluating, and clinical experience utilizing agents specifically designed to treat NMOSD to integrate them more effectively into practice and maximize patient outcomes
• Recognize evolutions in available evidence and guidance regarding the diagnosis and treatment of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) to more effectively manage these patients.